Key facts
- Perelel’s last known valuation is $172.0M (Nov 2025).
- It has raised $37.2M across 2 recorded rounds; the latest was Seed Round ($4.0M) in Oct 2025.
- Notable investors include Unilever Ventures, Selva Ventures, Prelude Growth Partners, Aimee Song, Alexandra Weiss — 17 tracked in total.
- Perelel has filed 2 Form Ds with the SEC since 2023, most recently Nov 2025 ($4.0M sold to 4 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Perelel
Funding rounds
2 roundsAbout Perelel
Operator of a fertility, prenatal, and postnatal vitamins brand intended for every stage of motherhood. The company offers doctor-formulated vitamin packs, bioavailable ingredients, and clean formulations tailored to life stages from fertility through perimenopause, enabling women seeking targeted nutritional support to maintain overall wellness and meet their evolving nutrient needs.
- Sector
- Consumer Products and Services (B2C)
- HQ
- Los Angeles, CA, United States
- Founded
- 2020
- Employees
- 12
- Website
- perelelhealth.com/
- Ownership
- Privately Held (backing)
Perelel doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Perelel shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Perelel in its N-PORT filings yet. We sweep new filings monthly.